SLF
NKTR icon

Sun Life Financial’s Nektar Therapeutics NKTR Stock Holding History

Sun Life Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10
Closed -$3K – 535
2019
Q3 		$3K Buy
10
+1
+11% +$367 ﹤0.01% 605
2019
Q2 		$5K Sell
9
-11
-55% -$5.52K ﹤0.01% 586
2019
Q1 		$10K Sell
20
-12
-38% -$7.11K ﹤0.01% 590
2018
Q4 		$16K Buy
32
+1
+3% +$604 ﹤0.01% 581
2018
Q3 		$29K Buy
31
+2
+7% +$1.71K 0.01% 553
2018
Q2 		$21K Buy
29
+24
+480% +$27.7K ﹤0.01% 587
2018
Q1 		$735 Buy
+5
New +$6.44K 0.01% 365

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Sun Life Financial's NKTR Position: Q4 2019 in Review

Sun Life Financial sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 10 shares — an estimated $3K sold.

Sun Life Financial first reported a position in NKTR in Q1 2018 and held it in 7 quarters. The position peaked at $29K in Q3 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • Sun Life Financial reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Sun Life Financial sold 10 Nektar Therapeutics shares in Q4 2019, an estimated $3K.
  • Sun Life Financial first reported a position in Nektar Therapeutics in Q1 2018 and held it in 7 quarters.
  • Sun Life Financial's Nektar Therapeutics position peaked at $29K in Q3 2018.
  • 281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Sun Life Financial's 13F filing for Q4 2019, filed 10 Feb 2020.